Unbelievable...., page-7

if Bell Potter has drawn a precise realistic focus on how things are in the Neuren house, then the problem is only of a temporal nature. without bothering anyone, it would be enough to postpone the start of the studies of 2591 for a few months, because we are in the presence of the classic case where there is no money in the short term, but even abundant in the medium term. it makes no sense to dilute the future value to have an immediate benefit, when it can be expected without particular repercussions. I base myself on what I learned in the last press release of 4E, where it is said that prudent spending will be conducted and that the great added value for Neuren is the usability without any restriction of the results that come from Acadia with Rett.if you really need to intercept about ten million, then just redo the experience of Lanstead, where Neuren has not diluted, but simply given actions to translate profit from the activity on the market.at the end of the day and due to the new uncertainties that have arisen these days, it is not convenient to force the time to get back into the field of experimentation. I think it is much more appropriate to perfect the preclinical in progress without emptying the boxes to ferry in key times, where the eventuality of receiving large prizes would become concrete and clearer and where the market will inevitably appreciate.a clearer picture of the situation is expected from the collection of the company's official statements in the last year, from the second half of 2020, with more certain relative times. between today and say June, there is an annual meeting with the shareholders that is certainly not the most favorable opportunity to put forward a hypothesis of a capital increase. rather, the right opportunity to redefine a strategy that is becoming clear and credible, to be linked to the request for authorization of a stock plan that rehabilitates the expired options to be refinanced